image
Healthcare - Biotechnology - NASDAQ - CH
$ 2.07
2.48 %
$ 205 M
Market Cap
-3.29
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ACIU stock under the worst case scenario is HIDDEN Compared to the current market price of 2.07 USD, AC Immune S.A. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ACIU stock under the base case scenario is HIDDEN Compared to the current market price of 2.07 USD, AC Immune S.A. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ACIU stock under the best case scenario is HIDDEN Compared to the current market price of 2.07 USD, AC Immune S.A. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ACIU

image
$2.8$2.8$2.6$2.6$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.415 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
27.3 M REVENUE
84.51%
-52.4 M OPERATING INCOME
2.32%
-50.9 M NET INCOME
6.12%
65.8 M OPERATING CASH FLOW
209.00%
-105 M INVESTING CASH FLOW
-160.39%
-1.12 M FINANCING CASH FLOW
-2.59%
990 K REVENUE
-12.93%
-19.4 M OPERATING INCOME
-4.04%
-19 M NET INCOME
-20.46%
-18.8 M OPERATING CASH FLOW
-317.09%
3.03 M INVESTING CASH FLOW
179.14%
-258 K FINANCING CASH FLOW
-30.96%
Balance Sheet AC Immune S.A.
image
Current Assets 172 M
Cash & Short-Term Investments 165 M
Receivables 2.2 M
Other Current Assets 4.3 M
Non-Current Assets 58.9 M
Long-Term Investments 415 K
PP&E 8.09 M
Other Non-Current Assets 50.4 M
71.67 %3.50 %21.83 %Total Assets$230.9m
Current Liabilities 101 M
Accounts Payable 2.66 M
Short-Term Debt 1.03 M
Other Current Liabilities 97.2 M
Non-Current Liabilities 17.8 M
Long-Term Debt 4.4 M
Other Non-Current Liabilities 13.4 M
81.89 %3.71 %11.30 %Total Liabilities$118.6m
EFFICIENCY
Earnings Waterfall AC Immune S.A.
image
Revenue 27.3 M
Cost Of Revenue 0
Gross Profit 27.3 M
Operating Expenses 79.7 M
Operating Income -52.4 M
Other Expenses -1.46 M
Net Income -50.9 M
30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)27m027m(80m)(52m)1m(51m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-191.80% OPERATING MARGIN
-191.80%
-186.44% NET MARGIN
-186.44%
-45.35% ROE
-45.35%
-22.05% ROA
-22.05%
-39.95% ROIC
-39.95%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AC Immune S.A.
image
80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -50.9 M
Depreciation & Amortization 2.16 M
Capital Expenditures -576 K
Stock-Based Compensation 5.47 M
Change in Working Capital 108 M
Others 95.6 M
Free Cash Flow 65.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AC Immune S.A.
image
ACIU has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 16
6. Ownership
Insider Ownership AC Immune S.A.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates AC Immune (ACIU) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.21 per share a year ago. zacks.com - 2 months ago
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseases Positive immunogenicity and good safety in interim results for wholly owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in Phase 2 trial in Parkinson's disease (PD) Additional ACI-7104.056 Phase 2 interim results (pharmacodynamics and biomarkers) expected in Q2 2025 Presentations at International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) highlight leadership in active immunotherapy and promising data on early-stage assets Cash resources of CHF 145.7 million as of March 31, 2025 provide funding into Q1 2027 before any potential milestones Lausanne, Switzerland, April 30, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the quarter ended March 31, 2025, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “AC Immune's portfolio of active immunotherapies for precision prevention of neurodegeneration continues to advance in clinical development. globenewswire.com - 2 months ago
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease globenewswire.com - 3 months ago
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company's industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseases Multiple presentations at the International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) showcasing the diversity of the company's precision medicine pipeline Lausanne, Switzerland, March 25, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025) taking place in Vienna, Austria, on April 1 – 5, 2025. AC Immune will host an industry symposium highlighting advances in the clinical development of active immunotherapies featuring key opinion leaders, industry experts and AC Immune leadership. globenewswire.com - 3 months ago
ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold? AC Immune's shares decline 18.3% in a month. While the company's pipeline progress is encouraging, we advise investors to remain on the sidelines for now. zacks.com - 3 months ago
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 billion plus royalties on sales upon commercialization ACI-24.060 ABATE Phase 1b/2 trial showed encouraging interim safety and tolerability data in Down syndrome (DS) cohort; further interim results in Alzheimer's disease (AD) and DS expected in 2025 Enrollment progress in JNJ-2056 (ACI-35.030) ReTain Phase 2b trial in preclinical AD patients triggered second milestone payment of CHF 24.6 million; JNJ-2056 granted U.S. FDA Fast Track Designation in AD ACI-7104.056 VacSYn Phase 2 trial demonstrated positive interim safety and immunogenicity results in Parkinson's disease (PD); further interim results in H1 2025 Cash resources of CHF 165.5 million at year end provides funding into Q1 2027, assuming no other milestones Lausanne, Switzerland, March 13, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the full year ended December 31, 2024, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We significantly advanced our leading position in the precision prevention of neurodegenerative diseases in 2024 through strong pipeline progress and the closing of a landmark deal with Takeda. globenewswire.com - 3 months ago
AC Immune (ACIU) Upgraded to Strong Buy: Here's What You Should Know AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 4 months ago
New Strong Buy Stocks for March 5th PFLT, COMM, BGC, NLY and ACIU have been added to the Zacks Rank #1 (Strong Buy) List on March 5, 2025. zacks.com - 4 months ago
Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU) The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. zacks.com - 4 months ago
New Strong Buy Stocks for January 31st ENS, SOPA, MC, SFIX and ACIU have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024. zacks.com - 5 months ago
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients AC Immune SA ACIU revealed data from a Phase 2 clinical trial of its wholly owned anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson's disease. benzinga.com - 7 months ago
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates AC Immune (ACIU) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of $0.42. This compares to loss of $0.22 per share a year ago. zacks.com - 11 months ago
8. Profile Summary

AC Immune S.A. ACIU

image
COUNTRY CH
INDUSTRY Biotechnology
MARKET CAP $ 205 M
Dividend Yield 0.00%
Description AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Contact Building B, Lausanne, 1015 https://www.acimmune.com
IPO Date Sept. 23, 2016
Employees 133
Officers Dr. Anke Post M.D., Ph.D. Chief Medical Officer Dr. Julien Rongere Ph.D. Senior Vice President of Regulatory Affairs & Quality Assurance Dr. Gary Anthony Waanders Ph.D. Senior Vice President of Investor Relations & Corporate Communications Mr. Mark Danton Executive Vice President of Information Systems & Artificial Intelligence Dr. Matthias Maurer Ph.D. SVice President & General Counsel Mr. Christopher Roberts Chief Financial Officer & Vice President of Finance Mr. Howard Donovan Chief HR Officer Dr. Oliver Sol M.D. Vice President & Head of Clinical Development Dr. Andrea Pfeifer Ph.D. Co-Founder, Chief Executive Officer & Director Mr. Piergiorgio Donati Chief Technical Operations Officer